443 related articles for article (PubMed ID: 19694467)
1. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.
Kreft AF; Martone R; Porte A
J Med Chem; 2009 Oct; 52(20):6169-88. PubMed ID: 19694467
[No Abstract] [Full Text] [Related]
2. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease: from pathology to therapeutic approaches.
Jakob-Roetne R; Jacobsen H
Angew Chem Int Ed Engl; 2009; 48(17):3030-59. PubMed ID: 19330877
[TBL] [Abstract][Full Text] [Related]
4. Gamma-secretase: a complex target for Alzheimer's disease.
Lundkvist J; Näslund J
Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
[TBL] [Abstract][Full Text] [Related]
5. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
Pollack SJ; Lewis H
Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of gamma-secretase inhibitors.
Josien H
Curr Opin Drug Discov Devel; 2002 Jul; 5(4):513-25. PubMed ID: 12197309
[TBL] [Abstract][Full Text] [Related]
7. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
Harrison T; Churcher I; Beher D
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
[TBL] [Abstract][Full Text] [Related]
8. Carbamate-appended N-alkylsulfonamides as inhibitors of gamma-secretase.
Bergstrom CP; Sloan CP; Lau WY; Smith DW; Zheng M; Hansel SB; Polson CT; Corsa JA; Barten DM; Felsenstein KM; Roberts SB
Bioorg Med Chem Lett; 2008 Jan; 18(2):464-8. PubMed ID: 18178084
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
10. Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.
Mayer SC; Kreft AF; Harrison B; Abou-Gharbia M; Antane M; Aschmies S; Atchison K; Chlenov M; Cole DC; Comery T; Diamantidis G; Ellingboe J; Fan K; Galante R; Gonzales C; Ho DM; Hoke ME; Hu Y; Huryn D; Jain U; Jin M; Kremer K; Kubrak D; Lin M; Lu P; Magolda R; Martone R; Moore W; Oganesian A; Pangalos MN; Porte A; Reinhart P; Resnick L; Riddell DR; Sonnenberg-Reines J; Stock JR; Sun SC; Wagner E; Wang T; Woller K; Xu Z; Zaleska MM; Zeldis J; Zhang M; Zhou H; Jacobsen JS
J Med Chem; 2008 Dec; 51(23):7348-51. PubMed ID: 19012391
[TBL] [Abstract][Full Text] [Related]
11. Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease.
Silvestri R
Med Res Rev; 2009 Mar; 29(2):295-338. PubMed ID: 18651582
[TBL] [Abstract][Full Text] [Related]
12. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting.
Rajendran L; Schneider A; Schlechtingen G; Weidlich S; Ries J; Braxmeier T; Schwille P; Schulz JB; Schroeder C; Simons M; Jennings G; Knölker HJ; Simons K
Science; 2008 Apr; 320(5875):520-3. PubMed ID: 18436784
[TBL] [Abstract][Full Text] [Related]
13. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease.
Vardy ER; Catto AJ; Hooper NM
Trends Mol Med; 2005 Oct; 11(10):464-72. PubMed ID: 16153892
[TBL] [Abstract][Full Text] [Related]
14. Secretases as therapeutic targets for Alzheimer's disease.
Woo HN; Baik SH; Park JS; Gwon AR; Yang S; Yun YK; Jo DG
Biochem Biophys Res Commun; 2011 Jan; 404(1):10-5. PubMed ID: 21130746
[TBL] [Abstract][Full Text] [Related]
15. Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease.
Zetterberg H
Scand J Clin Lab Invest; 2009; 69(1):18-21. PubMed ID: 19199126
[TBL] [Abstract][Full Text] [Related]
16. Discovery of gamma-secretase inhibitors efficacious in a transgenic animal model of Alzheimer's disease.
Asberom T; Zhao Z; Bara TA; Clader JW; Greenlee WJ; Hyde LA; Josien HB; Li W; McPhail AT; Nomeir AA; Parker EM; Rajagopalan M; Song L; Wong GT; Zhang L; Zhang Q; Pissarnitski DA
Bioorg Med Chem Lett; 2007 Jan; 17(2):511-6. PubMed ID: 17079141
[TBL] [Abstract][Full Text] [Related]
17. Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors.
Asberom T; Bara TA; Clader JW; Greenlee WJ; Guzik HS; Josien HB; Li W; Parker EM; Pissarnitski DA; Song L; Zhang L; Zhao Z
Bioorg Med Chem Lett; 2007 Jan; 17(1):205-7. PubMed ID: 17046254
[TBL] [Abstract][Full Text] [Related]
18. The role of heparan sulfate in the generation of Abeta.
Patey SJ
Drug News Perspect; 2006 Sep; 19(7):411-6. PubMed ID: 17080204
[TBL] [Abstract][Full Text] [Related]
19. Discovery of amide and heteroaryl isosteres as carbamate replacements in a series of orally active gamma-secretase inhibitors.
McBriar MD; Clader JW; Chu I; Del Vecchio RA; Favreau L; Greenlee WJ; Hyde LA; Nomeir AA; Parker EM; Pissarnitski DA; Song L; Zhang L; Zhao Z
Bioorg Med Chem Lett; 2008 Jan; 18(1):215-9. PubMed ID: 17988864
[TBL] [Abstract][Full Text] [Related]
20. Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors.
Gundersen E; Fan K; Haas K; Huryn D; Steven Jacobsen J; Kreft A; Martone R; Mayer S; Sonnenberg-Reines J; Sun SC; Zhou H
Bioorg Med Chem Lett; 2005 Apr; 15(7):1891-4. PubMed ID: 15780628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
